Marinus Pharmaceuticals reformulates, develops, and commercializes drugs to treat neurological, psychiatric, and pain disorders.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 7, 2022 | Post-IPO Equity | $60M | — | — | — | Detail |
Oct 31, 2022 | Post-IPO Debt | $32.50M | 1 | Sagard Healthcare Royalty Partners | — | Detail |
Apr 4, 2022 | Post-IPO Equity | $1.23M | — | — | — | Detail |
Mar 31, 2022 | Post-IPO Debt | $30M | 1 | Oaktree Capital Management | — | Detail |
May 17, 2021 | Post-IPO Debt | $45M | 1 | Oaktree Capital Management | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sagard Healthcare Royalty Partners | Yes | Post-IPO Debt |
Oaktree Capital Management | Yes | Post-IPO Debt |
Bain Capital Life Sciences | — | Post-IPO Equity |
Canaan Partners | — | Series C |
Domain Associates | — | Series C |
Foundation Medical Partners | — | Series C |
Sofinnova Investments | — | Series C |
RMI Partners | — | Series Unknown |